Based on these results, the U.S. Food and Drug Administration approved Aucatzyl for adults with this form of leukemia in November. “Patients with B-cell ALL need effective standalone treatment options ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL ... and about 45%-60% of adults have long-term disease-free survival. Acute refers to the relatively ...

In blood cancers such as chronic lymphocytic leukemia, B cells of the immune system multiply uncontrollably. One form of ...

The FELIX study was conducted across 34 sites in Spain, the United Kingdom, and the United States in adults with relapsed or refractory CD19-positive B-cell ALL. Eligible patients were at least 18 ...

for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approval was based on results from the ...

Professor Markus Sauer from the Biocentre of Julius-Maximilians-Universität (JMU) Würzburg in Bavaria, Germany ...

A similar study, also published earlier this year, showed promise for adults with leukemia ... He also has studied B-cell acute lymphoblastic leukemia. “… It’s incredibly important ...

Venetoclax is under clinical development by AbbVie and currently in Phase I for Primary Mediastinal B-Cell Lymphoma.

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the ...

Aucatzyl Approved for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Danziten (nilotinib) Kinase inhibitor For the treatment of adults with newly diagnosed Philadelphia chromosome ...